DaVita Inc. (DVA)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, DaVita traded at $182.08. I see a necessary, repetitive-care business: dialysis and related lab services for chronic kidney failure, run by 78,000 employees. That kind of demand can create a moat, but this is not a wide-moat compounder. FairStock's Lynch category calls it a SLOW GROWER—Shrinking, with profit down 0.7% a year over five years and revenue up 4.3%. The filed numbers support that caution: in fiscal year 2025 (period ended 2025-12-31), revenue was $13.6B and net income was $746.8M, down from fiscal year 2024 (period ended 2024-12-31) net income of $936.3M. Yet the latest quarter was better: in fiscal Q2 2026 (quarter ended 2026-06-30), revenue was $3.6B, net income $265.4M, and diluted EPS $4.02.

In plain English: DaVita runs kidney dialysis centers and related lab services, with about 78,000 employees. The business produces steady revenue and a lot of free cash, but profits have been uneven and the balance sheet carries high debt. At the recent price, the shares look inexpensive relative to earnings and cash flow, though the risk is higher than the low price alone suggests.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer